Liso-Cel Leads to Durable Responses in Second-Line Therapy in Relapsed/Refractory LBCL
June 5th 2022The phase 2 PILOT study showed encouraging overall response rates with lisacabtagene maraleucel in the second-line or beyond setting among patients with relapsed/refractory large B-cell lymphoma who did not receive hematopoietic stem cell transplantation.
Adding Daratumumab to RVd Improves MRD Negativity, PFS in Newly Diagnosed Myeloma
June 5th 2022Induction/consolidation daratumumab, lenalidomide, bortezomib and dexamethasone (RVd) outperformed RVd alone when it came to minimal residual disease and progression-free survival in patients with newly diagnosed, transplant-eligible myeloma.
Ph– B-Cell ALL Achieves MRD Negativity With Inotuzumab Plus Hyper-CVAD and Blinatumomab
June 4th 2022Chances of reaching complete remission and minimal residual disease negativity were greater with the addition of inotuzumab to hyper-CVAD with sequential blinatumomab in patients with Philadelphia chromosome–negative B-cell acute lymphoblastic lymphoma.
Relapsed Extranodal Natural Killer/T-cell Lymphoma May Benefit From Sugemalimab Therapy
June 3rd 2022Results of the GEMSTONE-201 study demonstrate complete responses were achieved in roughly one-third of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma who were treated with sugemalimab.
Julie Vose, MD, MBA, Discusses Novel Treatment Options for Hematologic Malignancies
July 29th 2021Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center, discusses novel treatment options for patients with hematologic malignancies at the 2021 American Society of Clinical Oncology Annual Meeting.